These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11001391)

  • 1. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
    Garufi C; Brienza S; Pugliese P; Aschelter AM; Bensmaine ; Bertheault-Cvitkovic F; Nisticò C; Giunta S; Caterino M; Giannarelli D; Cosimelli M; Lévi F; Terzoli E
    Anticancer Drugs; 2000 Jul; 11(6):495-501. PubMed ID: 11001391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
    Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
    J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
    Lévi F; Zidani R; Brienza S; Dogliotti L; Perpoint B; Rotarski M; Letourneau Y; Llory JF; Chollet P; Le Rol A; Focan C
    Cancer; 1999 Jun; 85(12):2532-40. PubMed ID: 10375099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
    Giacchetti S; Perpoint B; Zidani R; Le Bail N; Faggiuolo R; Focan C; Chollet P; Llory JF; Letourneau Y; Coudert B; Bertheaut-Cvitkovic F; Larregain-Fournier D; Le Rol A; Walter S; Adam R; Misset JL; Lévi F
    J Clin Oncol; 2000 Jan; 18(1):136-47. PubMed ID: 10623704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
    Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
    Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
    Garufi C; Bria E; Vanni B; Zappalà AM; Sperduti I; Terzoli E
    Br J Cancer; 2003 Nov; 89(10):1870-5. PubMed ID: 14612895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
    Lévi F; Zidani R; Misset JL
    Lancet; 1997 Sep; 350(9079):681-6. PubMed ID: 9291901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
    Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
    Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
    Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
    Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
    Farker K; Merkel U; Wedding U; Hippius M; Höffken K; Hoffmann A
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):31-7. PubMed ID: 16425969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients.
    Terzoli E; Garufi C; Zappalà AR; Vanni B; Pugliese P; Cappellini GA; Aschelter AM; Perrone M; Giannarelli D
    J Cancer Res Clin Oncol; 2004 Aug; 130(8):445-52. PubMed ID: 15205945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
    Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
    Cattel L; La Grotta G; Infante L; Passera R; Arpicco S; Brusa P; Bumma C
    Farmaco; 2003 Dec; 58(12):1333-8. PubMed ID: 14630248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
    Bertheault-Cvitkovic F; Jami A; Ithzaki M; Brummer PD; Brienza S; Adam R; Kunstlinger F; Bismuth H; Misset JL; Lévi F
    J Clin Oncol; 1996 Nov; 14(11):2950-8. PubMed ID: 8918492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
    Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
    Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
    Sagawa T; Tsuji Y; Takayanagi N; Hirayama Y; Sakamaki S; Chiba H; Iyama S; Oku T; Sato Y; Takahashi M; Takayama T; Niitsu Y
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):537-43. PubMed ID: 12722689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer].
    Lu JW; Zhou ZF; Yin BJ; Liu DL; Feng JF; Zhu LJ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):695-7. PubMed ID: 16438895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
    Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Mabro M; Artru P; Gilles V; Lotz JP; Izrael V; Krulik M;
    Eur J Cancer; 2001 May; 37(8):1000-5. PubMed ID: 11334725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
    Zori Comba A; Blajman C; Richardet E; Bella S; Vilanova M; Cóppola F; Van Kooten M; Rodger J; Giglio R; Balbiani L; Perazzo F; Montiel M; Chacón M; Pujol F; Mickiewicz E; Cazap E; Recondo G; Lastiri F; Simon J; Wasserman E; Schmilovich A
    Eur J Cancer; 2001 May; 37(8):1006-13. PubMed ID: 11334726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.